Precise pathological assessment plays a key role in proper patient management in nonseminoma germ cells tumor.
作者信息
Sosnowski Roman, Ligaj Marcin
机构信息
Department of Urooncology, M. Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
Department of Pathology, M. Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
出版信息
Cent European J Urol. 2013;66(3):271-2. doi: 10.5173/ceju.2013.03.art6.
Abstract
摘要
相似文献
1
Precise pathological assessment plays a key role in proper patient management in nonseminoma germ cells tumor.精确的病理评估在非精原细胞瘤性生殖细胞肿瘤的恰当患者管理中起着关键作用。
Cent European J Urol. 2013;66(3):271-2. doi: 10.5173/ceju.2013.03.art6.
2
3
Oncological outcomes in patients with stage I testicular seminoma and nonseminoma: pathological risk factors for relapse and feasibility of surveillance after orchiectomy.I 期睾丸精原细胞瘤和非精原细胞瘤患者的肿瘤学结局：复发的病理危险因素和睾丸切除术 后监测的可行性。
Diagn Pathol. 2013 Apr 8;8:57. doi: 10.1186/1746-1596-8-57.
4
Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance.临床Ⅰ期睾丸生殖细胞肿瘤主动监测患者复发模式。
J Clin Oncol. 2015 Jan 1;33(1):51-7. doi: 10.1200/JCO.2014.56.2116. Epub 2014 Aug 18.
5
Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases.睾丸生殖细胞肿瘤的晚期复发：122例病例的描述性分析
J Urol. 2005 Mar;173(3):824-9. doi: 10.1097/01.ju.0000154013.96349.36.
6
[Expression of CD117 in human testicular germ cell tumors and its diagnostic value for seminoma and nonseminoma].[CD117在人睾丸生殖细胞肿瘤中的表达及其对精原细胞瘤和非精原细胞瘤的诊断价值]
Zhonghua Nan Ke Xue. 2008 Jan;14(1):38-41.
7
Optimal Management of High-risk Stage I Nonseminoma Germ Cell Tumor: Active Intervention is the Preferred Option.高危Ⅰ期非精原细胞瘤生殖细胞肿瘤的最佳治疗策略：积极干预是首选。
Eur Urol Focus. 2019 Sep;5(5):704-705. doi: 10.1016/j.euf.2019.09.009. Epub 2019 Sep 27.
8
Oncological Outcomes in Japanese Men Undergoing Orchiectomy for Stage I Testicular Germ Cell Tumor.接受睾丸切除术治疗Ⅰ期睾丸生殖细胞肿瘤的日本男性患者的肿瘤学结局。
Curr Urol. 2015 Jul;8(2):84-90. doi: 10.1159/000365695. Epub 2015 Jul 10.
9
Lymph Node Yield in Primary Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumors.原发性腹膜后淋巴结清扫术治疗非精原细胞瘤生殖细胞肿瘤中的淋巴结检出数。
J Urol. 2015 Aug;194(2):386-91. doi: 10.1016/j.juro.2015.03.100. Epub 2015 Mar 28.
10
Testicular Cancer, Version 2.2015.睾丸癌临床实践指南（2015 年第 2 版）
J Natl Compr Canc Netw. 2015 Jun;13(6):772-99. doi: 10.6004/jnccn.2015.0092.
本文引用的文献
1
Lymphovascular invasion in testicular germ cell tumors: clinicopathological correlates.睾丸生殖细胞肿瘤中的淋巴管浸润：临床病理相关性
Cent European J Urol. 2013;66(3):266-70. doi: 10.5173/ceju.2013.03.art5. Epub 2013 Nov 18.
2
EAU guidelines on testicular cancer: 2011 update.EAU 睾丸癌指南：2011 年更新版。
Eur Urol. 2011 Aug;60(2):304-19. doi: 10.1016/j.eururo.2011.05.038. Epub 2011 May 25.
3
Multicentre risk-adapted management for stage I non-seminomatous germ cell tumours.I期非精原细胞性生殖细胞肿瘤的多中心风险适应性管理
Ann Oncol. 2005 Dec;16(12):1915-20. doi: 10.1093/annonc/mdi397. Epub 2005 Aug 26.
4
Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial.临床I期非精原细胞瘤性睾丸生殖细胞肿瘤复发的危险因素：德国睾丸癌研究组试验结果
J Clin Oncol. 2003 Apr 15;21(8):1505-12. doi: 10.1200/JCO.2003.07.169.
5
Treatment of testicular germ-cell cancer: a cochrane evidence-based systematic review.睾丸生殖细胞癌的治疗：一项循证医学系统评价
Cancer Treat Rev. 2002 Oct;28(5):237-53. doi: 10.1016/s0305-7372(02)00059-2.
6
Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis.I期精原细胞瘤监测管理中复发的预后因素：一项汇总分析。
J Clin Oncol. 2002 Nov 15;20(22):4448-52. doi: 10.1200/JCO.2002.01.038.
Zotero 插件